Singapore, Oct. 21 -- Swedish firm Moberg Pharma AB has signed a distribution agreement with South Korea headquartered DongKoo Bio & Pharma Co., Ltd for MOB-015 in the Republic of Korea. Under the agreement DongKoo is granted exclusive rights to market and sell MOB-015 in the Republic of Korea. Moberg Pharma assumes production and supply responsibility.

DongKoo will conduct registration activities in the Republic of Korea, and will be marketing, distributing and selling MOB-015 in the Republic of Korea upon completion of registration."This is the fourth commercial agreement for MOB-015, this time with the market leader in dermatology in Korea with excellent coverage of the dermatology clinics. We look forward to work with DongKoo and mak...